PASG - Passage BIO, Inc.
IEX Last Trade
0.65
0.010 1.508%
Share volume: 0
Last Updated: Thu 26 Dec 2024 08:21:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.64
0.01
1.53%
Fundamental analysis
27%
Profitability
36%
Dept financing
13%
Liquidity
50%
Performance
15%
Performance
5 Days
0.51%
1 Month
-13.26%
3 Months
1.78%
6 Months
-28.42%
1 Year
-32.03%
2 Year
-49.11%
Key data
Stock price
$0.65
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.49 - $1.79
52 WEEK CHANGE
-$35.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: William Chou
Region: US
Website: passagebio.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: passagebio.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.
Recent news